


HIV PRE-EXPOSURE PROPHYLAXIS ALGORITHM

Recent findings from clinical trials have shown that daily oral antiretroviral preexposure prophylaxis (PrEP) with a fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) in men who have sex with men (MSM), men and women in heterosexual HIV-discordant couples, and heterosexual men and women demonstrated substantial reduction in the rate of HIV acquisition. The CDC has published a clinical practice guideline for PrEP use for the prevention of HIV infection in MSM, heterosexual women and men, and IV drug users.



REFERENCES

Centers for Disease Control and Prevention: US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States - 2017 Update: A Clinical Practice Guideline. <https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf>. Published March 2018. Accessed July 1, 2020.

(Rev. 7/2020)